As part of the reorganisation, the sites in Dresden and Frankfurt will be closed and only the headquarters in Boston will remain. CEO Ameet Nathwani explained that clinical trials of the promising therapeutic approach should begin by the end of the year.
The decision comes at a time when many biotech start-ups are under high funding pressure and are forced to prioritise their resources more strictly.
Dewpoint is currently in the final rounds of raising private funding. Industry experts see the streamlining as a necessary measure to preserve the company's chances in a market characterised by intense competition. Whether the reorganisation will succeed and Dewpoint can maintain its position as an innovation leader in the field of condensate research is likely to be decided in the coming months.
News of "IT BOLTWISE Fachmagazin" from 08.08.2025
